Holen Sie sich die Stockscreener-App
0.4425
0.68%
0.003
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Zacks Investment Research
Humacyte Director Paul Brian Kuznik Receives 125,000 Stock Options with $0.478 Exercise Price - Kalkine Media
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - Zacks Investment Research
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
Humacyte Director D. Scott Coward Files Form 3 Reporting No Beneficial Ownership - Kalkine Media
Humacyte, Inc.Common Stock (NQ: HUMA - The Chronicle-Journal
Humacyte (NASDAQ: HUMA) director now holds 50,000 shares - Stock Titan
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Humacyte CEO to speak in New York on Sept. 16 - Stock Titan
Hospitals can keep an emergency blood-vessel graft for 36 months, up from 18 - Stock Titan
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Business Wire
Humacyte Inc. Warrant (HUMAW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Humacyte Inc. Warrant (HUMAW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
HC Wainwright raises Humacyte price target to $4 - scanx.trade
Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq - Stock Titan
Humacyte Inc. Warrant (HUMAW) Peer Comparison – Compare with Others - Value Research
Humacyte plans November FDA filing for dialysis access use By Investing.com - Investing.com Nigeria
Humacyte Plans November 2026 Supplemental BLA Submission for ATEV Dialysis Access Based on Phase 3 Data - Quiver Quantitative
Humacyte plans November FDA filing for dialysis access use - investing.com
Price to sales forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Investigation into Humacyte continues after FDA cites manufacturing violations and lawsuit proceeds. - Pluang
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Morningstar
Humacyte ATEV shows superiority in Phase 3 V012 study - scanx.trade
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Moomoo
Humacyte (HUMA) Shares: Records a 7.28% Decrease to $0.68 on the Day; Next Session - vinanet.vn
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Quiver Quantitative
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.25 - Moomoo
Humacyte (HUMA) Q2 2026 Earnings Call Transcript - AOL.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Australia
Humacyte publishes Phase 3 trial results in Lancet journal - Investing.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Canada
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com India
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - The Manila Times
Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results - TradingView
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis - Stock Titan
Fresenius Medical Care stock trades close to recent NYSE levels as Humacyte stake sale draws attenti - Ad-hoc-news.de
MSN Money - MSN
Major Humacyte (HUMA) holder sells shares under 10b5‑1 plan - Stock Titan
Humacyte Announces First Symvess Implants in Arizona by Phoenix Vascular Surgeon Jeromy Brink - Quiver Quantitative
A bioengineered blood vessel is ready off the shelf for urgent surgery - Stock Titan
HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Nigeria
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women - Yahoo Finance
2.40%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):